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ABSTRACT
Objective: To investigate the mechanisms of quinolone resistance and the association with
other resistance markers among Esherichia coli (E. coli) strains isolated from outpatient with
urinary tract infection in north of Algeria. Methods: A total of 30 nalidixic acid-resistant E.
coli isolates from outpatient with urinary tract infections from January 2010 to April 2011 in
north of Algeria (Bejaia) were studied. Antimicrobial susceptibility was determined by disc
diffusion assay, minimal inhibitory concentrations (MIC) of quinolone were determined by
microdilution. Mutations in the Quinolone Resistance-Determining Region (QRDR) of gyrA
and parC genes and screening for qnr (A, Band S) and bla genes were done by PCR and DNA
sequencing. Results: Most of the E. coli isolates (56.66%) were shown to carry mutations in gyrA
and parC 19yrA: Ser83Leu + Asp87Asn and parC:Ser80Ue). While, 16.66% had only an alteration
in gyrA: Ser83Leu. One isolate produced qnrB-like and two qnrS-like. Four isolates were CTX-
M-15 producers associated with TEM-l producing in one case. Co-expression of blacTX_M_
15 and qnrB was determined in one E. coli isolate. Conclusions: Our findings suggested the
community emergence of gyrA and parC alterations and Qnr determinants that contributed to the
development and spread of fluoroquinolone resistance in Algerian E. coli isolates.
1. Introduction
Escherichia coli (E. coli) is a major cause of urinary
tract infections (UTI). Quinolones are commonly used to
treat UTI due to E. CoWl]. These synthetic antimicrobial
agents include nalidixic acid and ciprofloxacin which is a
fluoroquinolone (FQ) with a wide spectrum of antibacterial
activity in vitro, particularly against gram negative
hacterialzl. The extensive use of FQ has led to an increasing
resistance in E. coli[3J. Resistance to quinolone occurs
as a result of chromosomic and plasmidic mechanisms.
Chromosomic-mediated quinolone resistance concerns
an accumulation of mutations in the Quinolone Resistance
Determining Region (QRDR) primarily in DNA gyrase (gyrA),
then in topoisomerase IV (parC). It can be associated with
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decreased outer membrane permeability and/or with an
overexpression of the efflux pump systemsl-l. Plasmid-
mediated quinolone resistance (PMQR) was first described
in 1998[51. Since then, five major groups of qnr determinants
(qnrA, qnrS, qnrB, qnrC and qnrD) have been identifiedls-sl,
Two additional PMQR determinants, the AAC(6')Ib-cr
enzyme, which acetylates not only aminoglycosides but also
ciprofloxacin and norfloxacin[lO] and quinolone extrusion
by QepA or OqxAB[ll, 12] have been also described. The
association between PMQR and multidrug resistant isolates
producing Extended Spectrum Beta-Lactamas (ESBL) has
been reported in urinary Enterobacteriaceae isolates in
AlgeriaI13, 14] and in different countriesltsl,
Fluoroquinolone resistance in E. coli is an important issue
all over the world. To date there is no publication from
Algeria evaluating the genetic determinants of resistance
to this class of antimicrobials in E. coli causing community
acquired urinary tract infections (no results on Pubbledj,
The aim of our study was to investigate the mechanisms
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Table 1
Primers used in this study.
Gene Primers
gyrA gyrA1  ACGTACTAGGCAATGACTGG
gyrA2 AGAAGTCGCCGTCGATAGAAC
parC parC1 AGTATGCGATGTCTGAACTG
parC2 CTCAATAGCAGCTCGGAATA
qnrA qnrA1 ATTTCTCACGCCAGGATTTG
qnrA2 GATCGGCAAAGGTTAGGTCA
qnrB qnrB1 GATCGTGAAAGCCAGAAAGG
qnrB2 ACGATGCCTGGTAGTTGTCC
qnrS qnrS1 ACGACATTCGTCAACTGCAA
qnrS2 TAAATTGGCACCCTGTAGGC
blaCTX-M blaCTX-M-A2 CTTCCAGAATAAGGAATC
 628R CCTTTCATCCATGTCACCA
 405F GTGGCGATGAATAAGCTGA
blaCTX-M-B2 CCGTTTCCGCTATTACAA
blaTEM blaTEM-A TAAAATTCTTGAAGACG
blaTEM-B TTACCAATGCTTAATCA
l i l )462-
of quinolone resistance and the association with other
resistance markers among E. coli strains isolated from
outpatient with UTI in north of Algeria.
2. Materials and methods
2.1. Bacterialstrains
Thirty non-repetitive nalidixic acid-resistant E.
coli isolates from community-acquired UTI in private
laboratories of medical analysis in the region of Bejaia
(North Algeria) from January 2010 to April 2011 were
included in this study. These isolates were identified by
API 20E identification system (BioMerieux, France). E. coli
ATCC25922 was used for susceptibility testing control. The
following ~ -lactamase-producing isolates were used
as control isolates: Enterobacter aerogenes CF 2403 (E.
aerogenes) for TEM, Klebsiella pneumoniae (K pneurrwniae)
KpS12 for SHV; and K pneurrwniae Bhe CD13 for CTX-M.
Qnr-positive strains provided by Pro J Vila and Dr. A.
Fabrega were used as positive controls: Enterobacter cloacae
(E. cloacae) for qnrA1,K pneurrwniae positive for qnrBl and
Salrrwnella enierica (S. etuerica] serovar Saintpaul positive
for qnrSi.
2.2. Antibioticsusceptibility testing
Susceptibility to different antimicrobials was performed
by disc diffusion method on Mueller-Hinton agar and was
interpreted according to Clinical and Laboratory Standards
Institute recommendations[l6J. Tested antibiotics included
norfloxacin, ofloxacin, ciprofloxacin, amoxicillinlclavulanic
acid, cefotaxime, ceftazidime, cefoxitin, aztreonam,
imipenem, gentamycin, kanamycin, tobramycin, amikacin,
and cotrimoxazole (Oxoid Ltd., Basingstoke, UK).
The nalidixic acid, norfloxacin, ofloxacin, ciprofloxacin and
levofloxacin minimum inhibitory concentration (MIC) were
determined by broth microdilution method with cation-
adjusted Mueller-Hinton broth (Difco Laboratories, Detroit,
Mich.) according to Clinical and Laboratory Standards
Institute recommendationsltel.
2.3. Phenotypic ESBL detection
Extended-Spectrum beta-Lactamase production was
detected by a double-disk synergy test (DDST) and was
performed by placing disks of ceftazidime, cefotaxime
and aztreonam at a distance of 20 mm (centre to centre)
from a disk with amoxicillinlclavulanic acid (20/10 p.g).
Enhancement of the inhibition zone between the disks
containing clavulanic acid and cefotaxime, ceftazidime or
aztreonam indicated the ESBLproductionli"l.
2.4. Analysis of quinolone resistance-determining regions
(QRDRs) ofgyrA and parC genes
The QRDR of gyrA and parC were amplified using the
primers showed in Table 1. PCR conditions were as follows:
initial denaturation step of 5 min at 94 ·e, 1 min at 94 ·e,
1 min at the annealing temperature (54 ·e for gyrA and 55 ·e
for parC) and 1 min at 72 ·e for 30 cycles, final extension
step was 10 min at 72 ·e[lSJ. Reaction mixes without a DNA
template served as negative controls. Amplified fragments
were purified (Qiagen kit, Hilden, Germany).
l
l
Al
l
l
crx_M crx_M_ 2
crx_ _B2
lCPr blCPr -
blCPr -
Nucleotide sequences were determined using the BigDye
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems).
The gyrA and parC nucleotide sequences and the deduced
amino acids were compared with that of E. coli K12 using
clustalw alignment program.
2.5. MultiplexPCR detection ofthe qnr genes
Screening for the qnrA, qnrB and qnrS genes was carried
out by a multiplex PCR amplification using specific primers
(fable 1)according to Robicsek et al2006[l9J.
2.6. Detection and characterization ofbla genes
Isolates positive for the DDST were screened for the
presence of blacrx_M, blaTEM and blasHV by PCR as previously
describedlzol, PCR products were sequenced and the DNA
alignments and the deduced amino acid sequences were
examined using the BLAST program.
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Table 2
MICs values (mg/L) and chromosomic and plasmid mediated resistance in E. coli quinolone resistant isolates.
Isolate Mutations NAL NOR OFX CIP LEV QNR ESBL Resistance phenotype
GyrA ParC
KB426 WT WT 32 1 1 0,5 0,25 qnrS - -
KB302 Ser83Leu WT 64 1 0.5 0,25 0,5 - - SXT
AB364 Ser83Leu WT >256 2 2 2 2 - - AMC-CN-TOB-SXT
MB409 Ser83Leu WT 32 1 0,5 0,25 0,25 - - -
LB415 Ser83Leu WT 256 0,5 0,5 <0,25 0,25 - - -
LB423 Ser83Leu WT 64 2 1 0,25 0,25 - - -
DB336 Ser83Leu/Asp87Asn WT >256 >256 128 64 64 - - -
KB308 Ser83Leu/Asp87Asn WT >256 128 64 64 32 - - -
AB305 Ser83Leu/Asp87Asn Ser80Ile >256 256 32 64 8 - - -
KB312 Ser83Leu/Asp87Asn Ser80Ile >256 >256 >256 >256 >256 - - -
KB338 Ser83Leu/Asp87Asn Ser80Ile >256 256 128 64 32 - - SXT
DB339 Ser83Leu/Asp87Asn Ser80Ile >256 256 32 16 8 - - SXT
MB348 Ser83Leu/Asp87Asn Ser80Ile >256 >256 64 128 32 - - -
DB370 Ser83Leu/Asp87Asn Ser80Ile >256 256 128 32 64 - - -
KB408 Ser83Leu/Asp87Asn Ser80Ile >256 256 64 32 16 - - -
KB412 Ser83Leu/Asp87Asn Ser80Ile >256 128 128 32 32 - - FOX-SXT
DB413 Ser83Leu/Asp87Asn Ser80Ile >256 128 16 16 8 - CTX-M-15 CTX-CAZ-ATM
MB418 Ser83Leu/Asp87Asn Ser80Ile >256 256 32 16 16 - - -
KB420 Ser83Leu/Asp87Asn Ser80Ile >256 128 32 16 8 - - K-SXT
LB437 Ser83Leu/Asp87Asn Ser80Ile >256 128 32 64 64 - - -
LB435 Ser83Leu/Asp87Asn Ser80Ile >256   64 16 16 8 - - AMC-SXT
MB446 Ser83Leu/Asp87Asn Ser80Ile >256 256 32 64 16 - - -
KB452 Ser83Leu/Asp87Asn Ser80Ile >256 >256 128 128 32 - - -
KB460 Ser83Leu/Asp87Asn Ser80Ile >256 >256 64 64 16 - - -
LB443 Ser83Leu/Asp87Asn Ser80Ile >256 >256 128 128 64 qnrB CTX-M-15 AMC-CTX-CAZ-ATM-CN-
K-TOB-SXT
DB462 Ser83Leu/Asp87Asn Glu84Lys >256   32 32 16 32 qnrS - AMC
AB341 Ser83Leu/Asp87Tyr Ser80Ile >256 256 128 64 64 - - AMC-FOX-K-SXT
LB403 Ser83Val/Asp87Gly Ser80Ile >256   32 16 2 4 - - K-SXT
MB337 Ser83Leu/Asp87Asn Ser80Ile/Glu84Val >256 >256 64 32 32 - CTX-M-15 
/TEM-1
CTX-CAZ-ATM-CN-SXT
KB402 Ser83Leu/Asp87Asn Ser80Ile/Glu84Val >256 256 32 64 8 - CTX-M-15 AMC-CTX-CAZ-ATM-CN-
K-SXT
NAL: nalidixic acid; NOR: norfloxacin; OFX: ofloxacin; CIP: ciprofloxacin; LEV: levofloxacin; WT: wild type;  AMC: amoxicillin-clavulanic 
acid; CTX: cefotaxime; CAZ: ceftazidime; FOX: cefoxitin; ATM: aztreonam; CN: gentamycin; K: kanamycin; TOB: tobramycin; SXT: 
cotrimoxazole.
3. Results
3.1. Antibiotic susceptibility testing
l l i l f i )462-
while, all isolates remained susceptible to imipenem and
amikacin (fable 2).
Eighty percent (24/30) of the 30 nalidixic acid-
resistant isolates showed a decrease in susceptibility to
fluoroquinolones (norfloxacin, ofloxacin, ciprofloxacin and
levofloxacin) (fable 2).
Among these isolates, 40% (12/30) were resistant to
cotrimoxazole, 20% (6/30) were resistant to amoxicillin/
clavulanic acid, 13.33% (4/30) were resistant to kanamycin,
cefotaxime, ceftazidime, aztreonam and gentamycin and
6.66% (2/30) were resistant to cefoxitin and tobramycin,
3.2. Analysis of quinolone resistance-determining regions
(QRDRs)
Mostof the E. coli isolates (22/30) presented point mutations
in QRDRs at the codon 83 (Ser-Leu/val) and 8? (Asp-Asnl
Tyr/Gly) in gyrA gene and at the codon 80 (Ser80-He) and!
or 84 (Glu84-VallLys) in pare gene. However, No amino
acid change in QRDRsof gyrA and parC was detected in one
isolate (KB426) (fable2).
/ )
- - -
O i ?
i ?
i ?
i ?
i ?
O i ?
i ?
O ? i ?
i ?
i ? -
O i ? - - -
i ?
i ? -
? i ?
i ? -
i ?
i ?
i ?
i ? - - - - - - -
-
O i ?
i ? - -
! ? l
? i ? - - - - - -
-l
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-
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:
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3.3. Detection ofqnr genes
Among 30 non-repetitive nalidixic acid-resistant E. coli
isolates, three (10%) were qnr-positive: including one qnrB-
like positive (LB443) and two qnrS-like positive (KB426 and
DB462) (Table 2). However, qnrA was not identified in any of
the tested nalidixic acid resistant isolates.
3.4. Characterization ofESBLs
The disk diffusion method showed synergy between
ceftazidime, cefotaxime, aztreonam, and amoxicillin
clavulanic acid in four isolates (DB413, LB402, MB337 and
LB443) suggesting the production of extended-spectrum
heta-Iactamase (ESBL). PCR and sequence analysis of the
deduced amino acid showed the presence of blaGrx-M-15 in all
tested isolates associated with blarnM-l in one case.
The co-expression of blaGrx_M_15 and qnrB was determined
in one E. coli isolate (LB443) (Table 2).
4. Discussion
E. coli is a main cause of urinary tract infections in the
community. The extensive use of fluoroquinolones to
treat these infections has led to an increasing resistance
in E. coli[3]. To date there is no publications from Algeria
evaluating the genetic determinants of resistance to this
class of antimicrobials in E. coli causing community
acquired urinary tract infections. In this study, 30
uropathogenic E. coli isolates were analyzed in terms
of quinolone susceptibility and chromosomic/plasmidic
quinolone resistance mechanisms.
Analysis of QRDRshowed that no amino acid changes was
detected in gyrA or parC proteins in 1/30 isolate (KB426)
for which MIC of nalidixic acid was 32 mg/L and remained
susceptible to fluoroquinolones (MIC of ciprofloxacin 0.5 mg/I),
whereas at least one amino acid substitution in the gyrA
protein at the codon 83 (Ser83LeuIVall was detected in
29/30 E. coli isolates. This alteration in gyrA alone leads
to high levels of resistance to nalidixic acid (MIC ranging
from 32 mg/L to 256 mg/L) and a reduced susceptibility
to fluoroquinolones (MIC of ciprofloxacin ~ 2 mg/L). An
additional mutation in the Asp87 codon of gyrA is associated
with a greater increase in fluoroquinolone resistance (MIC of
ciprofloxacin 64 mg/L).
Moreover, parC gene is a secondary target for quinolone
resistancelnl, Point mutations at codon 80 in parC QRDRs
(Ser80 Ile) and at the position 84 (Glu84 ValILys) were found
in 70% (21/30) and 10% (10/30) of E. coli isolates respectively.
Previous studies also demonstrated that the most prevalent
amino acid mutations were Ser83Leu/Asp87Asn in gyrA
and Ser80Ile/Glu84Val in parC and contribute to MIC
change in clinical and community E. coli isolates[22, 23J.
Thus, expression of high- level fluoroquinolone resistance
in Enterobacteriaceae requires the presence of multiple
mutations in gyrA and/or parCgenes.
Among the seventeen E. coli isolates with the same types
of mutation (Ser83Leu/Asp87Asn in gyrA and Ser80Ile in
parC) differences in MICs values for fluoroquinolones were
observed (MICs of ciprofloxacine ranging from 16 mg/L to
256 mg/L). This can be explained by other mechanisms
implicated in fluoroquinolone resistance. Changes in
permeability and active effiux are mechanisms that cannot
be excluded and may enhance development of resistance
and contribute to the selection of fluoroquinolone-resistant
isolates in the course of treatments with these antibiotiosl-l.
The multiplex PCR showed that the qnr genes was present
in 10% (3/30) of nalidixic acid resistant uropathogenic
E. coli isolates. Among these three isolates, one was
qnrB-like positive and two were qnrS-like positive. The
presence of qnrB and qnrS are usually reported among
qnr positive isolates from different part of the world[24J. It
has been shown that in Algeria, the most prevalent qnr
determinant is qnrB followed by qnrS determinant at least in
Klebsiella pneumoniae[15] and Enterobacter cloacae[25].
Previous reports have pointed out that qnr determinants
confer resistance to quinolones (nalidixic acid) and reduced
the susceptibility to fluoroquinoloneslzel. Furthermore, it has
been described that the expression of qnr genes increases
the mutant prevention concentration compared to strains
without this genes and thus favors selection of mutations in
gyrA and parC[27]. In our case, a qnrSpositive isolate (KB426)
which carried none mutation in QRDR region of gyrA and
parC showed only an increased in nalidixic acid resistance
with MIC of 32 mg/L for nalidixic acid and 0.5 mg/L
for fluoroquinolone. While, the qnrB (LB443) and the qnrS
(DB462) positive isolates which carried two mutations in
gyrA (Ser83Leu and Asp87Ala) and one mutation in parC
(Ser80Ileand Glu84Lysrespectively) had a high level of both
quinolone and fluoroquinolone resistance (MIC of nalidixic
acid of 256 mg/L and MIC of ciprofloxacin of 128 mg/L and
16 mg/L respectively). Previous works also suggested that
PMQR and chromosomal resistance mechanisms are additive
and can enhance the quinolone resistance of clinical
isolates[28J.
Some of the community-acquired quinolone-resistant
E. coli isolates presented a multiresistance phenotype. Thus,
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40% were cotrimoxazole resistant. Among of these isolates,
eight (26, 66%) were also resistant to cephalosporins and/
or aminoglycosides. As it was previously reportedlzsl, the
high rate of resistance to sulfonamides is related with the
commonly prescription of these molecules for urinary tract
infections.
Moreover, four of these multidrug resistant E. coli isolates
were positive for ESBL production (DB413, LB443, MB337
and KB402) for CTX-M-15 type associated with TEM-l
type in one isolate (MB337). CTX-M type ESBLs have been
extensively reported for the past 15 years in both community
and nosocomial isolates and a strong linkage between their
production and quinolone resistance has been reported in
Etuerobacteriaceaeeos. In our study, we reported in a one
isolate (LB443) the co-expression of qnrB and blacTX-M-15
genes. The association between qnrB and CTX-M-15 and
CTX-M-28 was detected in clinical Enterobacterial isolates
from Algeria[13, 141. As it was also described in Francelstl,
Singaporelszl, Sweden[331 and Moroccolwl,
The plasmid mediated-quinolone resistance (PMQR)
genes are usually associated with the same mobile
genetic elements as those of ESBL genes. The presence
of mechanisms for broad spectrum resistance on the
same plasmid, highlights the clinical importance of these
genes and the potential for selection and dissemination
of resistance to various antimicrobials through improper
quinolone use.
Our findings suggested the community emergence of gyrA
and parC alterations and qnr determinants that contributed
to the development and spread of fluoroquinolone resistance
in E. coli isolates in our region. Taking into account that
such antimicrobials are in most cases the choice for
community acquired Urinary Tract Infections (UTI), such
increase is a main cause of concern for doctors and health
authorities. Especially noteworthy is the dissemination of
the plasmid-mediated quinolone resistance (PMQR) like the
Qnr determinants. The presence of these determinants in the
outpatient is worrisome, because of the potential spread of
plasmids in a scenario of uncontrolled oral quinolone usage.
Furthermore, plasmids usually harbor other resistance genes
which can compromise therapeutic options against species
that were formerly truly susceptible. Further research should
be done to track the evolution of these determinants in our
population.
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